Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Demand for weight-loss medications has reached unprecedented levels in the United States. Estimates suggest that between 15 and 24 million Americans could benefit from GLP-1 receptor agonist therapy based on current obesity prevalence, yet fewer than 5 million currently use these medications—revealing a massive treatment gap that continues to grow each year.

Current Usage Statistics: How Many People Take GLP-1 Medications

Exact numbers remain difficult to pinpoint because GLP-1 medications like semaglutide are prescribed across multiple channels: brand-name products through traditional insurance, compounded versions through telehealth platforms, and direct-to-consumer services. Industry analysts estimate that as of 2024, between 4 and 6 million Americans actively use GLP-1 receptor agonists for weight management, up from fewer than 1 million in 2021. This represents growth of over 400% in three years, though prescriptions continue to face supply constraints and affordability barriers.

Prescription data from pharmacy benefit managers and retail chains shows consistent month-over-month increases in GLP-1 fills. Medicare beneficiaries represent roughly 20-25% of all GLP-1 users, while commercial insurance covers another 35-40%. The remaining users access these medications through compounded pharmacies, self-pay options, or cash-based telehealth services—a segment that has grown rapidly due to cost concerns and insurance denials.

Why Demand for GLP-1 Weight Loss Therapy Is Exploding

The surge in GLP-1 adoption stems from multiple converging factors. Clinical trial data demonstrating average weight loss of 15-22% of baseline body weight has shifted patient and provider perceptions about what's possible with medication. Celebrity endorsements and social media visibility have normalized discussion of weight-loss drugs, reducing stigma that historically kept many people from pursuing pharmacologic treatment. Additionally, media coverage of supply shortages for diabetes indications has paradoxically increased awareness among people seeking weight management.

Insurance coverage gaps drive significant interest in accessible alternatives. Many insurance plans either deny GLP-1 coverage for weight loss or require extensive prior authorization and failed diet attempts. This barrier has made compounded semaglutide and tirzepatide attractive options, as they bypass traditional insurance workflows and become available within days rather than months. Cost considerations also matter: while compounded medications represent an out-of-pocket expense, monthly prices often prove comparable to insurance copays when considering the total cost of treatment.

Demographics of GLP-1 Users: Who Is Getting Treated

GLP-1 users span diverse age groups and income levels, though early adopters skewed toward higher-income individuals with better healthcare access. Women represent approximately 60-65% of GLP-1 prescriptions across most reports, potentially reflecting higher baseline health-seeking behavior and comfort discussing weight management. Age distribution shows peak usage in the 35-65 year age range, though prescription rates among adults under 35 are accelerating rapidly due to direct-to-consumer marketing and telehealth platforms.

Geographic variation exists significantly, with urban and suburban areas showing higher penetration rates than rural regions. Socioeconomic factors influence whether patients access these medications through insurance (higher income) or compounded pharmacies (diverse income levels). Racial and ethnic differences in access persist, with non-Hispanic white and Asian American populations currently representing a larger proportion of users than Black and Hispanic populations—a disparity that likely reflects insurance coverage patterns and healthcare provider relationships rather than clinical need or interest.

Compounded Semaglutide as an Accessible Alternative

Compounded semaglutide from licensed 503A pharmacies offers an entry point for patients unable to access brand-name medications through insurance. These formulations contain the same active pharmaceutical ingredient as Ozempic but are manufactured in compounding facilities under strict FDA oversight. PlexusDx partners with licensed 503A compounding pharmacies to deliver semaglutide injections across all 50 states without requiring insurance approval, membership fees, or prior authorization—eliminating waiting periods that can stretch to months.

Pricing for compounded semaglutide injection starts at $149 per month, flat-rate regardless of dose adjustments. This transparent, no-surprises approach addresses a primary concern many patients express: fear that dose escalation will trigger cost increases. PlexusDx medications are HSA- and FSA-eligible, and the Precision Peptide Genetic Test ($99 add-on after first month) maps genetic variants affecting peptide pathways—helping identify whether semaglutide, tirzepatide, or dual-compound therapy aligns best with an individual's underlying biology.

Treatment Gaps and Barriers to Access

Despite soaring demand, massive treatment gaps persist. Approximately 70-75% of Americans meeting clinical criteria for GLP-1 therapy currently remain untreated, primarily due to insurance denials, supply constraints, and cost concerns. Many insurance plans restrict GLP-1 coverage to patients with diabetes or BMI above 35, excluding millions who would benefit clinically. Prior authorization requirements can delay treatment initiation by 4-8 weeks, during which patient motivation may wane.

Manufacturing capacity constraints for brand-name semaglutide (Ozempic, Wegovy) have eased somewhat but remain a bottleneck in some regions. Compounded formulations help address supply issues by distributing manufacturing across the nationwide network of 503A pharmacies. High out-of-pocket costs through traditional insurance copays—sometimes $300-500 monthly—drive many patients toward compounded alternatives or no treatment at all. Geographic provider shortages in primary care and obesity medicine mean many patients lack access to clinicians experienced in GLP-1 initiation and titration.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How many Americans currently use Ozempic or semaglutide for weight loss?

Current estimates range from 4 to 6 million Americans actively using GLP-1 medications for weight management, up from under 1 million in 2021. This explosive growth reflects increased awareness, clinical evidence, and expanding access through compounded pharmacies, though prescription demand continues to far exceed treatment supply. Many more millions meet clinical criteria but remain untreated due to insurance barriers and cost.

What clinical evidence supports GLP-1 medications for weight loss?

Randomized controlled trials demonstrate that semaglutide produces average weight loss of 15-22% of baseline body weight over 68 weeks of treatment, with benefits sustained as long as therapy continues. Tirzepatide, a dual GLP-1/GIP receptor agonist, shows even greater efficacy with weight loss up to 24% in clinical trials. These outcomes significantly exceed those achieved through lifestyle modification alone or older weight-loss medications.

Why might someone choose compounded semaglutide over brand-name Ozempic?

Compounded semaglutide from licensed 503A pharmacies offers several advantages: faster access (days instead of weeks or months), no insurance approval required, flat pricing that doesn't change with dose adjustments ($149/month), and availability in all 50 states. Many patients find compounded options more affordable than insurance copays and appreciate transparent, predictable costs without surprise bills. PlexusDx serves patients across diverse financial situations seeking efficient, straightforward access.

Are there safety differences between brand-name and compounded semaglutide?

Both contain identical active pharmaceutical ingredients and are subject to FDA oversight—brand-name through FDA approval pathways and compounded versions through strict 503A pharmacy regulations. Compounded medications do not carry FDA approval labels, but rigorous quality standards ensure sterility, potency, and purity. Patients should discuss any medical history and medications with their prescriber regardless of which semaglutide source they choose.

How can I know if semaglutide, tirzepatide, or combination therapy is best for my genetics?

PlexusDx Precision Peptide Genetic Test analyzes key variants including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 across 14 metabolic pathways and 49 peptides. This peptide-pathway genetic assessment (different from pharmacogenomic testing) identifies how your biology influences GLP-1 response, GIP sensitivity, and appetite-regulation mechanisms. The test costs $99 as an add-on after your first month of treatment and helps personalize medication selection.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves